Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Osajin is the major bioactive iso avone present in the fruit of Maclura pomifera. It has antitumor, antioxidant, and anti-inflammatory activities.
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 2,610 | 待询 | ||
5 mg | ¥ 6,630 | 待询 | ||
10 mg | ¥ 9,960 | 待询 | ||
25 mg | ¥ 17,100 | 待询 | ||
50 mg | ¥ 25,800 | 待询 | ||
100 mg | ¥ 39,100 | 待询 |
产品描述 | Osajin is the major bioactive iso avone present in the fruit of Maclura pomifera. It has antitumor, antioxidant, and anti-inflammatory activities. |
体外活性 | Osajin shows growth inhibitory activity on six human cancer cell lines, including kidney, lung, prostate, breast, melanoma and colon cancer cells. Osajin obviously reduces the viability of human NPC cells in a dose-dependent manner. Osajin causes apoptosis in human NPC cells through multiple apoptotic pathways, including the extrinsic death receptor pathway, and intrinsic pathways relying on mitochondria and endoplasmic reticulum stress[1][2]. |
体内活性 | The cardioprotection provided by osajin and pomiferin treatment results from the suppression of oxidative stress and this correlates with improved ventricular function. Osajin and pomiferin attenuate the myocardial dysfunction provoked by ischemia-reperfusion. This is confirmed by an increase in both antioxidant enzyme values and total antioxidant activity[3]. |
别名 | NSC 21565, CID 95168 |
分子量 | 404.46 |
分子式 | C25H24O5 |
CAS No. | 482-53-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Osajin 482-53-1 Others CID-95168 NSC21565 NSC 21565 NSC-21565 CID 95168 CID95168 Inhibitor inhibitor inhibit